Summarized by Masters of Longevity from Longevity Technology.
A five-year, €13 million consortium will advance EXO-101 toward clinical trials.
Key Takeaways
- Consortium was formed to push EXO-101 into trials.
- Eliquent has joined to provide regulatory development expertise.
- Plans are translational and remain noncausal and preliminary.
